Ainos Announces $1.75M Follow-on Funding

Seeking AlphaJan 24 09:25 ET

Ainos, Inc. Announces Stock Consolidation

SAN DIEGO, CA / ACCESSWIRE / December 12, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos," or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care t

AccesswireDec 12, 2023 08:00 ET

Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement

Proceeds to fund company's clinical trials, commercial product launch, and working capital Initial conversion price set at $1.50 per shareSAN DIEGO, CA / ACCESSWIRE / September 25, 2023 / Ainos, Inc.

AccesswireSep 25, 2023 08:30 ET

Ainos Pursues Licensing Partners To Accelerate Five Candidates Of Its Low-dose Oral Interferon Formulation VELDONA To Phase 3 Trials And Commercialization

Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synt

Benzinga Real-time NewsOct 31, 2022 07:11 ET

Ainos Pursues Licensing Partners to Accelerate Five Candidates of Its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization

Clinical results thus far have shown low-dose oral interferon's promising efficacy as a new treatment or as an alternative to high-dose injectable interferonSAN DIEGO, CA / ACCESSWIRE / October 31, 20

AccesswireOct 31, 2022 07:05 ET

Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of Its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms

SAN DIEGO, CA / ACCESSWIRE / August 24, 2022 / $Ainos(AIMD.US)$ ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interfero

AccesswireAug 24, 2022 07:00 ET